LifeTech Scientific Corporation (1302.HK)
- Previous Close
1.620 - Open
1.630 - Bid 1.580 x --
- Ask 1.590 x --
- Day's Range
1.560 - 1.630 - 52 Week Range
1.560 - 3.030 - Volume
5,316,522 - Avg. Volume
5,576,204 - Market Cap (intraday)
7.362B - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
26.50 - EPS (TTM)
0.060 - Earnings Date Mar 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.69
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders worldwide. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, HeartR, and Konar-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; Futhrough endovascular needle systems; delivery systems, such as Fustar steerable and SteerEase introducers; Zoetrack guidewire; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; HearTone implantable cardiac pacing system; and SeQure snare systems, as well as pacemakers. The company is also involved in the biomedical research and development; properties leasing business; and manufacturing and trading of medical devices, as well as offers technical, consulting, and technology services. The company was founded in 1999 and is headquartered in Shenzhen, China.
www.lifetechmed.comRecent News: 1302.HK
Performance Overview: 1302.HK
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1302.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1302.HK
Valuation Measures
Market Cap
7.36B
Enterprise Value
6.10B
Trailing P/E
24.92
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.16
Price/Book (mrq)
2.02
Enterprise Value/Revenue
4.81
Enterprise Value/EBITDA
24.05
Financial Highlights
Profitability and Income Statement
Profit Margin
20.77%
Return on Assets (ttm)
4.92%
Return on Equity (ttm)
3.44%
Revenue (ttm)
1.27B
Net Income Avi to Common (ttm)
263.24M
Diluted EPS (ttm)
0.060
Balance Sheet and Cash Flow
Total Cash (mrq)
1.18B
Total Debt/Equity (mrq)
0.28%
Levered Free Cash Flow (ttm)
--